The Government has not made a specific assessment of the competitiveness of the prosthesis manufacturing industry. However, prosthetics form a key part of the wider medical technology sector, and work is underway with the main medical technology trade associations (including the British Healthcare Trades Association (BHTA)), under the aegis of the Ministerial Medical Technology Strategy Group to identify and address the competitiveness challenges across the sector and its supply-chains.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4070", "label" : {"_value" : "Biography information for Matt Hancock"} } , "answeringMemberConstituency" : {"_value" : "West Suffolk"} , "answeringMemberPrinted" : {"_value" : "Matthew Hancock"} , "dateOfAnswer" : {"_value" : "2014-09-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-09-08T16:20:12.4759148Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "26"} , "answeringDeptShortName" : {"_value" : "Business, Innovation and Skills"} , "answeringDeptSortName" : {"_value" : "Business, Innovation and Skills"} , "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prosthetics: Competition"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Innovation and Skills, what assessment he has made of the competitiveness of the prosthesis manufacturing industry.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"} } , "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"} , "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"} ], "uin" : "207338"} , {"_about" : "http://data.parliament.uk/resources/89567", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/89567/answer", "answerText" : {"_value" : "
In the period 1 September 2013 to 31 August 2014, decision makers issued sanctions to teachers after disciplinary hearings that differed from the sanctions recommended by the Professional Conduct Panel of the National College for Teaching and Leadership (NCTL) on seven occasions. Details are included within the table below.<\/p>
Number of Cases<\/p><\/td> | Recommendation of panel<\/p><\/td> | Final decision<\/p><\/td><\/tr> |
3<\/p><\/td> | No prohibition.<\/p><\/td> | Prohibition for life with opportunity to apply for the order to be set aside after a minimum period of two years.<\/p><\/td><\/tr> |
3<\/p><\/td> | Prohibition for life with opportunity to apply for the order to be set aside after a minimum period of five years.<\/p><\/td> | Prohibition for life with no opportunity to apply for the order to be set aside.<\/p><\/td><\/tr> |
1<\/p><\/td> | Prohibition for life with opportunity to apply for the order to be set aside after a minimum period of 10 years.<\/p><\/td> | Prohibition for life with no opportunity to apply for the order to be set aside.<\/p><\/td><\/tr><\/tbody><\/table> <\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1473", "label" : {"_value" : "Biography information for Mr David Laws"} } , "answeringMemberConstituency" : {"_value" : "Yeovil"} , "answeringMemberPrinted" : {"_value" : "Mr David Laws"} , "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-09-05T09:28:39.9580573Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "60"} , "answeringDeptShortName" : {"_value" : "Education"} , "answeringDeptSortName" : {"_value" : "Education"} , "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Teachers: Disciplinary Proceedings"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Education, on how many occasions in the last 12 months decision-makers within her Department have issued sanctions to teachers after disciplinary hearings that have differed from the sanctions recommended by the Professional Conduct Panel of the National College for Teaching and Leadership; and in what respects those sanctions have differed from the recommended sanctions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"} } , "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"} , "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"} ], "uin" : "207201"} , {"_about" : "http://data.parliament.uk/resources/89706", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/89706/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) clinical guideline \u2018Multiple sclerosis: Management of multiple sclerosis in primary and secondary care\u2019<\/em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient\u2019s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.<\/p> We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.<\/p> The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "207193"}
, {"_value" : "207203"}
, {"_value" : "207242"}
, {"_value" : "207243"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-05T11:00:42.0457982Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Multiple Sclerosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps (a) his Department and (b) NHS England have taken to ensure that accessible information is produced about multiple sclerosis treatment options.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"}
}
, "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"}
, "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"}
], "uin" : "207186"}
, {"_about" : "http://data.parliament.uk/resources/89711", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/89711/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) clinical guideline \u2018Multiple sclerosis: Management of multiple sclerosis in primary and secondary care\u2019<\/em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient\u2019s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.<\/p> We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.<\/p> The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "207186"}
, {"_value" : "207193"}
, {"_value" : "207203"}
, {"_value" : "207242"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-05T11:00:42.700064Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Multiple Sclerosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if he will take steps to ensure that regular reviews of treatment and care by multiple sclerosis (MS) specialists are available for all people with MS in England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"}
}
, "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"}
, "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"}
], "uin" : "207243"}
, {"_about" : "http://data.parliament.uk/resources/89716", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/89716/answer", "answerText" : {"_value" : " No such assessment has been made of the practicality and safety of the recycling of prosthesis components issued by the National Health Service, or the cost to the NHS of repairs to prostheses in each of the last five years.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "207348"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-05T09:43:48.3441767Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prosthetics"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the practicality and safety of the recycling of prosthesis components issued by the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"}
}
, "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"}
, "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"}
], "uin" : "207347"}
, {"_about" : "http://data.parliament.uk/resources/89717", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/89717/answer", "answerText" : {"_value" : " No such assessment has been made of the practicality and safety of the recycling of prosthesis components issued by the National Health Service, or the cost to the NHS of repairs to prostheses in each of the last five years.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "207347"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-05T09:43:48.422322Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prosthetics"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the cost to the NHS of repairs to prostheses in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"}
}
, "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"}
, "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"}
], "uin" : "207348"}
, {"_about" : "http://data.parliament.uk/resources/89720", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/89720/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) clinical guideline \u2018Multiple sclerosis: Management of multiple sclerosis in primary and secondary care\u2019<\/em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient\u2019s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.<\/p> We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.<\/p> The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "207186"}
, {"_value" : "207193"}
, {"_value" : "207203"}
, {"_value" : "207243"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-05T11:00:42.6024969Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Multiple Sclerosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent assessment he has made of the provision of licensed treatments for multiple sclerosis in the NHS in England; and if he will take steps to increase the availability of such treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"}
}
, "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"}
, "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"}
], "uin" : "207242"}
, {"_about" : "http://data.parliament.uk/resources/89724", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/89724/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) clinical guideline \u2018Multiple sclerosis: Management of multiple sclerosis in primary and secondary care\u2019<\/em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient\u2019s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.<\/p> We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.<\/p> The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "207186"}
, {"_value" : "207203"}
, {"_value" : "207242"}
, {"_value" : "207243"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-05T11:00:42.315179Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Multiple Sclerosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps he plans to take to increase the role of people with multiple sclerosis in decision-making processes relating to their treatment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"}
}
, "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"}
, "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"}
], "uin" : "207193"}
, {"_about" : "http://data.parliament.uk/resources/89726", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/89726/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) clinical guideline \u2018Multiple sclerosis: Management of multiple sclerosis in primary and secondary care\u2019<\/em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient\u2019s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.<\/p> We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.<\/p> The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-09-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "207186"}
, {"_value" : "207193"}
, {"_value" : "207242"}
, {"_value" : "207243"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-05T11:00:42.5026789Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-08-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Multiple Sclerosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if he will take steps to ensure that all people with relapsing remitting multiple sclerosis are invited to talk with a specialist about potential treatment options arising from new disease-modifying drugs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4037", "label" : {"_value" : "Biography information for Tom Blenkinsop"}
}
, "tablingMemberConstituency" : {"_value" : "Middlesbrough South and East Cleveland"}
, "tablingMemberPrinted" : [{"_value" : "Tom Blenkinsop"}
], "uin" : "207203"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 9, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|